Advertisement

FDA Grants Apixaban Expanded Indication for Venous Thromboembolism — Physician’s First Watch

Medical News |
August 25, 2014

FDA Grants Apixaban Expanded Indication for Venous Thromboembolism

By Larry Husten

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

The FDA has approved an expanded indication for the oral anticoagulant apixaban (Eliquis), the manufacturer announced late last week. Apixaban will now be indicated for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk for recurrent DVT and PE after initial therapy.

Approval of the supplemental new drug application was based on findings from the previously published AMPLIFY and AMPLIFY-EXT studies.

All three of the new oral anticoagulants — dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban — have now gained both the venous thromboembolism indication as well as the indication for stroke prevention in patients with nonvalvular atrial fibrillation. Rivaroxaban and apixaban are also approved for DVT prophylaxis following hip- or knee-replacement surgery.

Reader Comments (2)

TAPAS CHAKRABORTY Physician, Internal Medicine, Countess Of Chester Hospital

Journal watch is good in keep me updating.
Do you accept case report for publication and if so what's the limit of the word?

Mario Fernandes Physician, Hematology, Brazil

very good paper

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement